Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies.

Related Articles

Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies.

Front Pharmacol. 2016;7:299

Authors: Thompson MD, Capra V, Clunes MT, Rovati GE, Stankova J, Maj MC, Duffy DL

Abstract
Genetic variants associated with asthma pathogenesis and altered response to drug therapy are discussed. Many studies implicate polymorphisms in genes encoding the enzymes responsible for leukotriene synthesis and intracellular signaling through activation of seven transmembrane domain receptors, such as the cysteinyl leukotriene 1 (CYSLTR1) and 2 (CYSLTR2) receptors. The leukotrienes are polyunsaturated lipoxygenated eicosatetraenoic acids that exhibit a wide range of pharmacological and physiological actions. Of the three enzymes involved in the formation of the leukotrienes, arachidonate 5 lipoxygenase 5 (ALOX5), leukotriene C4 synthase (LTC4S), and leukotriene hydrolase (LTA4H) are all polymorphic. These polymorphisms often result in variable production of the CysLTs (LTC4, LTD4, and LTE4) and LTB4. Variable number tandem repeat sequences located in the Sp1-binding motif within the promotor region of the ALOX5 gene are associated with leukotriene burden and bronchoconstriction independent of asthma risk. A 444A > C SNP polymorphism in the LTC4S gene, encoding an enzyme required for the formation of a glutathione adduct at the C-6 position of the arachidonic acid backbone, is associated with severe asthma and altered response to the CYSLTR1 receptor antagonist zafirlukast. Genetic variability in the CysLT pathway may contribute additively or synergistically to altered drug responses. The 601 A > G variant of the CYSLTR2 gene, encoding the Met201Val CYSLTR2 receptor variant, is associated with atopic asthma in the general European population, where it is present at a frequency of ?2.6%. The variant was originally found in the founder population of Tristan da Cunha, a remote island in the South Atlantic, in which the prevalence of atopy is approximately 45% and the prevalence of asthma is 36%. In vitro work showed that the atopy-associated Met201Val variant was inactivating with respect to ligand binding, Ca(2+) flux and inositol phosphate generation. In addition, the CYSLTR1 gene, located at Xq13-21.1, has been associated with atopic asthma. The activating Gly300Ser CYSLTR1 variant is discussed. In addition to genetic loci, risk for asthma may be influenced by environmental factors such as smoking. The contribution of CysLT pathway gene sequence variants to atopic asthma is discussed in the context of other genes and environmental influences known to influence asthma.

PMID: 27990118 [PubMed – in process]

View full post on pubmed: asthma

Break for allergic asthma sufferers as ‘lifesaving’ drug subsidised – Herald Sun


Herald Sun

Break for allergic asthma sufferers as 'lifesaving' drug subsidised
Herald Sun
The Coalition will spend $5.4 million to make Omalizumab — an injectable medication used to treat severe asthma not controlled by corticosteroid inhalers — available to hundreds of patients across Australia. The drug is used to treat people who

and more »

View full post on asthma – Google News

Brentford star Alan Judge reprimanded after being found with too much asthma-treating drug Salbutamol in his system – getwestlondon


getwestlondon

Brentford star Alan Judge reprimanded after being found with too much asthma-treating drug Salbutamol in his system
getwestlondon
The Irishman, who has suffered from exercise-induced asthma since he was a child, was deemed to have too much Salbutamol, a common drug used for treating the condition via an inhaler, in his system. Judge has permission by the authorities to use it.
Alan Judge: Brentford midfielder given doping warningBBC Sport
Alan Judge warned for breaching anti-doping regulationsITV News

all 10 news articles »

View full post on asthma – Google News

AstraZeneca’s Severe Asthma Drug Positive in Phase III – Zacks.com


Wall Street Journal

AstraZeneca's Severe Asthma Drug Positive in Phase III
Zacks.com
These randomized, double-blind, parallel-group, placebo-controlled studies evaluated the safety and efficacy of benralizumab as an add-on therapy in the treatment of severe uncontrolled asthma with eosinophilic inflammation in patients aged 12 years
AstraZeneca's Asthma Drug Shows Positive ResultsWall Street Journal
AstraZeneca set to go head to head against GSK with asthma drugFinancial Times
AstraZeneca asthma drug hits goal, to enter competitive marketReuters
FierceBiotech –The Guardian –Philadelphia Business Journal
all 34 news articles »

View full post on asthma – Google News

AstraZeneca’s Asthma Drug Shows Positive Results – Wall Street Journal


Wall Street Journal

AstraZeneca's Asthma Drug Shows Positive Results
Wall Street Journal
Bing Yao, head of respiratory medicine at AstraZeneca's MedImmune unit, said benralizumab acted directly on the cells that are thought to cause attacks in patients with severe asthma. He said the Glaxo and Teva drugs, by contrast, act indirectly by
AstraZeneca set to go head to head against GSK with asthma drugFinancial Times
AstraZeneca asthma drug hits goal, to enter competitive marketReuters
AstraZeneca's asthma biologic hits PhIII target, but still behind rivalsFierceBiotech
The Guardian –Philadelphia Business Journal –MarketWatch
all 31 news articles »

View full post on asthma – Google News

AstraZeneca Asthma Drug Shows Positive Results – Wall Street Journal


Reuters

AstraZeneca Asthma Drug Shows Positive Results
Wall Street Journal
Bing Yao, head of respiratory medicine at the company's MedImmune unit, said benralizumab acted directly on the cells that are thought to cause attacks in severe asthma patients. He said the Glaxo and Teva drugs, by contrast, act indirectly by
AstraZeneca asthma drug hits goal, to enter competitive marketReuters
AstraZeneca climbs after positive asthma treatment resultsThe Guardian
AstraZeneca: Asthma drug trial results positiveMarketWatch
FierceBiotech –Nasdaq
all 13 news articles »

View full post on asthma – Google News

AstraZeneca asthma drug hits goal, to enter competitive market – Reuters


Reuters

AstraZeneca asthma drug hits goal, to enter competitive market
Reuters
L) drive to rebuild its portfolio of new medicines received a boost with positive results for an experimental biotech drug for severe asthma that the company previously flagged as a potential $2 billion-a-year seller. Benralizumab, which is likely to
AstraZeneca: Asthma drug trial results positiveMarketWatch
Astrazeneca Reports Results On Benralizumab Phase III Programme In Severe AsthmaNasdaq
TOP NEWS: AstraZeneca Gets Positive Benralizumab Phase III Trial ResultsLondon South East (registration) (blog)

all 6 news articles »

View full post on asthma – Google News

AstraZeneca boosted by good results for biotech asthma drug – Reuters


Reuters

AstraZeneca boosted by good results for biotech asthma drug
Reuters
LONDON AstraZeneca's (AZN.L) drive to rebuild its portfolio of new medicines received a boost on Tuesday with positive results for a biotech drug for severe asthma that the company has previously flagged as a potential $2 billion-a-year product.
AstraZeneca: Asthma drug trial results positiveMarketWatch
Astrazeneca Reports Results On Benralizumab Phase III Programme In Severe AsthmaNasdaq
TOP NEWS: AstraZeneca Gets Positive Benralizumab Phase III Trial ResultsLondon South East (registration) (blog)

all 4 news articles »

View full post on asthma – Google News

AstraZeneca: Asthma drug trial results positive – MarketWatch


Reuters UK

AstraZeneca: Asthma drug trial results positive
MarketWatch
LONDON–AstraZeneca PLC (AZN.LN) said Tuesday its potential new medicine benralizumab showed positive results in a Phase III trial for asthma treatment. The treatment "was well tolerated and achieved the primary endpoint in two pivotal Phase III …
AstraZeneca boosted by good results for biotech asthma drugReuters UK
Astrazeneca Reports Results On Benralizumab Phase III Programme In Severe AsthmaNasdaq
TOP NEWS: AstraZeneca Gets Positive Benralizumab Phase III Trial ResultsLondon South East (registration) (blog)

all 4 news articles »

View full post on asthma – Google News